Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 96

1.

Factors associated with receiving surgical treatment for menorrhagia in England and Wales: findings from a cohort study of the National Heavy Menstrual Bleeding Audit.

Geary RS, Gurol-Urganci I, Kiran A, Cromwell DA, Bansi-Matharu L, Shakespeare J, Mahmood T, van der Meulen J.

BMJ Open. 2019 Feb 19;9(2):e024260. doi: 10.1136/bmjopen-2018-024260.

2.

Antisense Inhibition of Glucagon Receptor by IONIS-GCGRRx Improves Type 2 Diabetes Without Increase in Hepatic Glycogen Content in Patients With Type 2 Diabetes on Stable Metformin Therapy.

Morgan ES, Tai LJ, Pham NC, Overman JK, Watts LM, Smith A, Jung SW, Gajdošík M, Krššák M, Krebs M, Geary RS, Baker BF, Bhanot S.

Diabetes Care. 2019 Feb 14. pii: dc181343. doi: 10.2337/dc18-1343. [Epub ahead of print]

PMID:
30765435
3.

Association of Timing of Sexual Partnerships and Perceptions of Partners' Concurrency With Reporting of Sexually Transmitted Infection Diagnosis.

Mercer CH, Jones KG, Geary RS, Field N, Tanton C, Burkill S, Clifton S, Sonnenberg P, Mitchell KR, Gravningen K, Johnson AM.

JAMA Netw Open. 2018 Dec 7;1(8):e185957. doi: 10.1001/jamanetworkopen.2018.5957.

4.

Integrated Assessment of the Clinical Performance of GalNAc3-Conjugated 2'-O-Methoxyethyl Chimeric Antisense Oligonucleotides: I. Human Volunteer Experience.

Crooke ST, Baker BF, Xia S, Yu RZ, Viney NJ, Wang Y, Tsimikas S, Geary RS.

Nucleic Acid Ther. 2019 Feb;29(1):16-32. doi: 10.1089/nat.2018.0753. Epub 2018 Dec 20.

5.

Sexual mixing in opposite-sex partnerships in Britain and its implications for STI risk: findings from the third National Survey of Sexual Attitudes and Lifestyles (Natsal-3).

Geary RS, Copas AJ, Sonnenberg P, Tanton C, King E, Jones KG, Trifonova V, Johnson AM, Mercer CH.

Int J Epidemiol. 2018 Dec 11. doi: 10.1093/ije/dyy237. [Epub ahead of print]

6.

Long-term Rate of Mesh Sling Removal Following Midurethral Mesh Sling Insertion Among Women With Stress Urinary Incontinence.

Gurol-Urganci I, Geary RS, Mamza JB, Duckett J, El-Hamamsy D, Dolan L, Tincello DG, van der Meulen J.

JAMA. 2018 Oct 23;320(16):1659-1669. doi: 10.1001/jama.2018.14997.

PMID:
30357298
7.

Antisense Inhibition of Protein Tyrosine Phosphatase 1B With IONIS-PTP-1BRx Improves Insulin Sensitivity and Reduces Weight in Overweight Patients With Type 2 Diabetes.

Digenio A, Pham NC, Watts LM, Morgan ES, Jung SW, Baker BF, Geary RS, Bhanot S.

Diabetes Care. 2018 Apr;41(4):807-814. doi: 10.2337/dc17-2132. Epub 2018 Feb 9.

PMID:
29439147
8.

Sociodemographic differences in symptom severity and duration among women referred to secondary care for menorrhagia in England and Wales: a cohort study from the National Heavy Menstrual Bleeding Audit.

Kiran A, Geary RS, Gurol-Urganci I, Cromwell DA, Bansi-Matharu L, Shakespeare J, Mahmood T, van der Meulen J.

BMJ Open. 2018 Feb 2;8(2):e018444. doi: 10.1136/bmjopen-2017-018444.

9.

Sexual identity, attraction and behaviour in Britain: The implications of using different dimensions of sexual orientation to estimate the size of sexual minority populations and inform public health interventions.

Geary RS, Tanton C, Erens B, Clifton S, Prah P, Wellings K, Mitchell KR, Datta J, Gravningen K, Fuller E, Johnson AM, Sonnenberg P, Mercer CH.

PLoS One. 2018 Jan 2;13(1):e0189607. doi: 10.1371/journal.pone.0189607. eCollection 2018.

10.

The Effects of 2'-O-Methoxyethyl Oligonucleotides on Renal Function in Humans.

Crooke ST, Baker BF, Pham NC, Hughes SG, Kwoh TJ, Cai D, Tsimikas S, Geary RS, Bhanot S.

Nucleic Acid Ther. 2018 Feb;28(1):10-22. doi: 10.1089/nat.2017.0693. Epub 2017 Nov 29.

11.

A step-wise approach to developing indicators to compare the performance of maternity units using hospital administrative data.

Geary RS, Knight HE, Carroll FE, Gurol-Urganci I, Morris E, Cromwell DA, van der Meulen JH.

BJOG. 2018 Jun;125(7):857-865. doi: 10.1111/1471-0528.15013. Epub 2017 Dec 15. Review.

12.

Sexual health clinic attendance and non-attendance in Britain: findings from the third National Survey of Sexual Attitudes and Lifestyles (Natsal-3).

Tanton C, Geary RS, Clifton S, Field N, Heap KL, Mapp F, Hughes G, Johnson AM, Cassell JA, Sonnenberg P, Mercer CH.

Sex Transm Infect. 2018 Jun;94(4):268-276. doi: 10.1136/sextrans-2017-053193. Epub 2017 Sep 29.

13.
14.

Cardiovascular and Metabolic Effects of ANGPTL3 Antisense Oligonucleotides.

Graham MJ, Lee RG, Brandt TA, Tai LJ, Fu W, Peralta R, Yu R, Hurh E, Paz E, McEvoy BW, Baker BF, Pham NC, Digenio A, Hughes SG, Geary RS, Witztum JL, Crooke RM, Tsimikas S.

N Engl J Med. 2017 Jul 20;377(3):222-232. doi: 10.1056/NEJMoa1701329. Epub 2017 May 24.

15.

The Effects of 2'-O-Methoxyethyl Containing Antisense Oligonucleotides on Platelets in Human Clinical Trials.

Crooke ST, Baker BF, Witztum JL, Kwoh TJ, Pham NC, Salgado N, McEvoy BW, Cheng W, Hughes SG, Bhanot S, Geary RS.

Nucleic Acid Ther. 2017 Jun;27(3):121-129. doi: 10.1089/nat.2016.0650. Epub 2017 Feb 1.

16.

Pharmacology of Antisense Drugs.

Bennett CF, Baker BF, Pham N, Swayze E, Geary RS.

Annu Rev Pharmacol Toxicol. 2017 Jan 6;57:81-105. doi: 10.1146/annurev-pharmtox-010716-104846. Epub 2016 Oct 10. Review.

PMID:
27732800
17.

Actual and preferred contraceptive sources among young people: findings from the British National Survey of Sexual Attitudes and Lifestyles.

Geary RS, Tomes C, Jones KG, Glasier A, Macdowall W, Datta J, Sonnenberg P, Wellings K, French RS, Mercer CH, Johnson AM.

BMJ Open. 2016 Sep 26;6(9):e011966. doi: 10.1136/bmjopen-2016-011966.

18.

Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials.

Viney NJ, van Capelleveen JC, Geary RS, Xia S, Tami JA, Yu RZ, Marcovina SM, Hughes SG, Graham MJ, Crooke RM, Crooke ST, Witztum JL, Stroes ES, Tsimikas S.

Lancet. 2016 Nov 5;388(10057):2239-2253. doi: 10.1016/S0140-6736(16)31009-1. Epub 2016 Sep 21.

PMID:
27665230
19.

Disposition and Pharmacokinetics of a GalNAc3-Conjugated Antisense Oligonucleotide Targeting Human Lipoprotein (a) in Monkeys.

Yu RZ, Gunawan R, Post N, Zanardi T, Hall S, Burkey J, Kim TW, Graham MJ, Prakash TP, Seth PP, Swayze EE, Geary RS, Henry SP, Wang Y.

Nucleic Acid Ther. 2016 Dec;26(6):372-380. Epub 2016 Aug 8.

PMID:
27500733
20.

Integrated Safety Assessment of 2'-O-Methoxyethyl Chimeric Antisense Oligonucleotides in NonHuman Primates and Healthy Human Volunteers.

Crooke ST, Baker BF, Kwoh TJ, Cheng W, Schulz DJ, Xia S, Salgado N, Bui HH, Hart CE, Burel SA, Younis HS, Geary RS, Henry SP, Bhanot S.

Mol Ther. 2016 Oct;24(10):1771-1782. doi: 10.1038/mt.2016.136. Epub 2016 Jun 30.

21.

The gender dimensions of social networks and help-seeking behaviors of young adults in Soweto, South Africa.

Meagley K, Schriver B, Geary RS, Fielding-Miller R, Stein AD, Dunkle KL, Norris SA.

Glob Health Action. 2016 Jun 3;9:31138. doi: 10.3402/gha.v9.31138. eCollection 2016.

22.

Changes in conceptions in women younger than 18 years and the circumstances of young mothers in England in 2000-12: an observational study.

Wellings K, Palmer MJ, Geary RS, Gibson LJ, Copas A, Datta J, Glasier A, Scott RH, Mercer CH, Erens B, Macdowall W, French RS, Jones K, Johnson AM, Tanton C, Wilkinson P.

Lancet. 2016 Aug 6;388(10044):586-95. doi: 10.1016/S0140-6736(16)30449-4. Epub 2016 May 24.

23.

Disposition and Pharmacology of a GalNAc3-conjugated ASO Targeting Human Lipoprotein (a) in Mice.

Yu RZ, Graham MJ, Post N, Riney S, Zanardi T, Hall S, Burkey J, Shemesh CS, Prakash TP, Seth PP, Swayze EE, Geary RS, Wang Y, Henry S.

Mol Ther Nucleic Acids. 2016 May 3;5:e317. doi: 10.1038/mtna.2016.26.

24.

Pharmacokinetic and Pharmacodynamic Investigations of ION-353382, a Model Antisense Oligonucleotide: Using Alpha-2-Macroglobulin and Murinoglobulin Double-Knockout Mice.

Shemesh CS, Yu RZ, Gaus HJ, Seth PP, Swayze EE, Bennett FC, Geary RS, Henry SP, Wang Y.

Nucleic Acid Ther. 2016 Aug;26(4):223-35. doi: 10.1089/nat.2016.0607. Epub 2016 Mar 31.

PMID:
27031383
25.

Lack of Interactions Between an Antisense Oligonucleotide with 2'-O-(2-Methoxyethyl) Modifications and Major Drug Transporters.

Yu RZ, Warren MS, Watanabe T, Nichols B, Jahic M, Huang J, Burkey J, Geary RS, Henry SP, Wang Y.

Nucleic Acid Ther. 2016 Apr;26(2):111-7. doi: 10.1089/nat.2015.0588. Epub 2016 Mar 9.

PMID:
26959999
26.

Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia.

Gaudet D, Alexander VJ, Baker BF, Brisson D, Tremblay K, Singleton W, Geary RS, Hughes SG, Viney NJ, Graham MJ, Crooke RM, Witztum JL, Brunzell JD, Kastelein JJ.

N Engl J Med. 2015 Jul 30;373(5):438-47. doi: 10.1056/NEJMoa1400283.

27.

Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study.

Tsimikas S, Viney NJ, Hughes SG, Singleton W, Graham MJ, Baker BF, Burkey JL, Yang Q, Marcovina SM, Geary RS, Crooke RM, Witztum JL.

Lancet. 2015 Oct 10;386(10002):1472-83. doi: 10.1016/S0140-6736(15)61252-1. Epub 2015 Jul 22.

PMID:
26210642
28.

Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides.

Geary RS, Norris D, Yu R, Bennett CF.

Adv Drug Deliv Rev. 2015 Jun 29;87:46-51. doi: 10.1016/j.addr.2015.01.008. Epub 2015 Feb 7. Review.

29.

Evaluating youth-friendly health services: young people's perspectives from a simulated client study in urban South Africa.

Geary RS, Webb EL, Clarke L, Norris SA.

Glob Health Action. 2015 Jan 23;8:26080. doi: 10.3402/gha.v8.26080. eCollection 2015.

30.

Predictive dose-based estimation of systemic exposure multiples in mouse and monkey relative to human for antisense oligonucleotides with 2'-o-(2-methoxyethyl) modifications.

Yu RZ, Grundy JS, Henry SP, Kim TW, Norris DA, Burkey J, Wang Y, Vick A, Geary RS.

Mol Ther Nucleic Acids. 2015 Jan 20;4:e218. doi: 10.1038/mtna.2014.69.

31.
32.

Targeting APOC3 in the familial chylomicronemia syndrome.

Gaudet D, Brisson D, Tremblay K, Alexander VJ, Singleton W, Hughes SG, Geary RS, Baker BF, Graham MJ, Crooke RM, Witztum JL.

N Engl J Med. 2014 Dec 4;371(23):2200-6. doi: 10.1056/NEJMoa1400284.

33.

Mechanism of alternative complement pathway dysregulation by a phosphorothioate oligonucleotide in monkey and human serum.

Henry SP, Jagels MA, Hugli TE, Manalili S, Geary RS, Giclas PC, Levin AA.

Nucleic Acid Ther. 2014 Oct;24(5):326-35. doi: 10.1089/nat.2014.0491. Epub 2014 Aug 5.

PMID:
25093529
34.

Barriers to and facilitators of the provision of a youth-friendly health services programme in rural South Africa.

Geary RS, Gómez-Olivé FX, Kahn K, Tollman S, Norris SA.

BMC Health Serv Res. 2014 Jun 16;14:259. doi: 10.1186/1472-6963-14-259.

35.

The effectiveness of youth centers in increasing use of sexual and reproductive health services: a systematic review.

Zuurmond MA, Geary RS, Ross DA.

Stud Fam Plann. 2012 Dec;43(4):239-54. doi: 10.1111/j.1728-4465.2012.00324.x. Review.

PMID:
23239245
36.

Clinical pharmacokinetics of second generation antisense oligonucleotides.

Yu RZ, Grundy JS, Geary RS.

Expert Opin Drug Metab Toxicol. 2013 Feb;9(2):169-82. doi: 10.1517/17425255.2013.737320. Epub 2012 Dec 12. Review.

PMID:
23231725
37.

Clinical pharmacological properties of mipomersen (Kynamro), a second generation antisense inhibitor of apolipoprotein B.

Crooke ST, Geary RS.

Br J Clin Pharmacol. 2013 Aug;76(2):269-76. doi: 10.1111/j.1365-2125.2012.04469.x. Review.

38.

Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trial.

Visser ME, Wagener G, Baker BF, Geary RS, Donovan JM, Beuers UH, Nederveen AJ, Verheij J, Trip MD, Basart DC, Kastelein JJ, Stroes ES.

Eur Heart J. 2012 May;33(9):1142-9. doi: 10.1093/eurheartj/ehs023. Epub 2012 Apr 16.

39.

Efficacy of apolipoprotein B synthesis inhibition in subjects with mild-to-moderate hyperlipidaemia.

Akdim F, Tribble DL, Flaim JD, Yu R, Su J, Geary RS, Baker BF, Fuhr R, Wedel MK, Kastelein JJ.

Eur Heart J. 2011 Nov;32(21):2650-9. doi: 10.1093/eurheartj/ehr148. Epub 2011 May 18.

PMID:
21593041
40.

In vitro metabolic stabilities and metabolism of 2'-O-(methoxyethyl) partially modified phosphorothioate antisense oligonucleotides in preincubated rat or human whole liver homogenates.

Baek MS, Yu RZ, Gaus H, Grundy JS, Geary RS.

Oligonucleotides. 2010 Dec;20(6):309-16. doi: 10.1089/oli.2010.0252. Epub 2010 Nov 30.

PMID:
21117960
41.

Phase I study of the c-raf-1 antisense oligonucleotide ISIS 5132 in combination with carboplatin and paclitaxel in patients with previously untreated, advanced non-small cell lung cancer.

Fidias P, Pennell NA, Boral AL, Shapiro GI, Skarin AT, Eder JP Jr, Kwoh TJ, Geary RS, Johnson BE, Lynch TJ, Supko JG.

J Thorac Oncol. 2009 Sep;4(9):1156-62. doi: 10.1097/JTO.0b013e3181b2793f.

42.

Effect of dose and plasma concentration on liver uptake and pharmacologic activity of a 2'-methoxyethyl modified chimeric antisense oligonucleotide targeting PTEN.

Geary RS, Wancewicz E, Matson J, Pearce M, Siwkowski A, Swayze E, Bennett F.

Biochem Pharmacol. 2009 Aug 1;78(3):284-91. doi: 10.1016/j.bcp.2009.04.013. Epub 2009 Apr 22.

PMID:
19393225
43.

Antisense oligonucleotide pharmacokinetics and metabolism.

Geary RS.

Expert Opin Drug Metab Toxicol. 2009 Apr;5(4):381-91. doi: 10.1517/17425250902877680 . Review.

PMID:
19379126
44.

Lack of pharmacokinetic interaction of mipomersen sodium (ISIS 301012), a 2'-O-methoxyethyl modified antisense oligonucleotide targeting apolipoprotein B-100 messenger RNA, with simvastatin and ezetimibe.

Yu RZ, Geary RS, Flaim JD, Riley GC, Tribble DL, vanVliet AA, Wedel MK.

Clin Pharmacokinet. 2009;48(1):39-50. doi: 10.2165/0003088-200948010-00003.

PMID:
19071883
45.

Cross-species comparison of in vivo PK/PD relationships for second-generation antisense oligonucleotides targeting apolipoprotein B-100.

Yu RZ, Lemonidis KM, Graham MJ, Matson JE, Crooke RM, Tribble DL, Wedel MK, Levin AA, Geary RS.

Biochem Pharmacol. 2009 Mar 1;77(5):910-9. doi: 10.1016/j.bcp.2008.11.005. Epub 2008 Nov 14.

PMID:
19056355
46.

Oral delivery of antisense oligonucleotides in man.

Tillman LG, Geary RS, Hardee GE.

J Pharm Sci. 2008 Jan;97(1):225-36.

PMID:
17721945
47.

Inhaled CD86 antisense oligonucleotide suppresses pulmonary inflammation and airway hyper-responsiveness in allergic mice.

Crosby JR, Guha M, Tung D, Miller DA, Bender B, Condon TP, York-DeFalco C, Geary RS, Monia BP, Karras JG, Gregory SA.

J Pharmacol Exp Ther. 2007 Jun;321(3):938-46. Epub 2007 Mar 26.

PMID:
17389243
48.

Cross-species pharmacokinetic comparison from mouse to man of a second-generation antisense oligonucleotide, ISIS 301012, targeting human apolipoprotein B-100.

Yu RZ, Kim TW, Hong A, Watanabe TA, Gaus HJ, Geary RS.

Drug Metab Dispos. 2007 Mar;35(3):460-8. Epub 2006 Dec 15.

PMID:
17172312
49.

Anti-inflammatory activity of inhaled IL-4 receptor-alpha antisense oligonucleotide in mice.

Karras JG, Crosby JR, Guha M, Tung D, Miller DA, Gaarde WA, Geary RS, Monia BP, Gregory SA.

Am J Respir Cell Mol Biol. 2007 Mar;36(3):276-85. Epub 2006 Sep 21.

PMID:
16990616

Supplemental Content

Loading ...
Support Center